Clinical trial NCT06187701: Co-Active Therapeutic Theatre (Co-ATT) for Dual-Diagnosis Patients
Official title: Pilot Study on the Use of the Co-Active Therapeutic Theatre (Co-ATT) Manualised Model of Drama Therapy for the Treatment of Patients With Co-occurring Primary Psychiatric and Substance Use Disorders
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Mental Health Issue
Substance Use Disorders
Keywords: Drama therapy
Psychiatric symptom severity
Subjective quality of life
Overall functioning
Lead sponsor: Boston Medical Center
Sponsor class: OTHER
First posted: 2024-01-03
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Drama Therapy involves of the use of theatrical techniques (such as script development, acting exercises, improvisation, etc.) to help treat patients' mental illness and improve their functioning and overall sense of wellbeing.

This study will evaluate the effectiveness of a specific version of drama therapy for the treatment of patients suffering from both mental illness (such as depression, bipolar disorder, schizophrenia, etc.) and one or more substance use disorders. The study will also assess participants feelings and thoughts about the drama therapy intervention (such as whether or not they enjoyed it and if/how they found it helpful).

The drama therapy intervention will consist of one group drama therapy session per week, for a total of twelve weeks (i.e., total twelve sessions) followed by a single performance (with composition of the audience determined by unanimous agreement of the participants) of the dramatic work (script) produced by the participants during the course of the drama therapy intervention.


Eligibility criteria: Inclusion Criteria:

* Diagnosed with at least one primary psychiatric disorder, and
* Diagnosed with at least one substance use disorder
* Both disorders active (i.e., meeting DSM-V criteria for each disorder (i.e., with ongoing psychiatric symptoms and ongoing substance use)
* Enrolled in the Addiction Psychiatry Treatment Program (APTP) at Boston Medical Center (i.e., scheduled for follow-up appointments with therapist and/or psychiatrist in APTP).
* Currently taking medications and those not currently taking medications

Exclusion Criteria:

* Incarcerated persons
* Pregnant women
* Inability to understand and/or sign informed consent form

Primary outcomes:
measure: Change in substance use
timeFrame: baseline, 12 weeks
measure: Change in psychiatric symptom severity for a history of Major Depressive Disorder (MDD)
timeFrame: baseline, 12 weeks
measure: Change in psychiatric symptom severity given a history of bipolar disorder with the BDRS
timeFrame: baseline, 12 weeks
measure: Change in psychiatric symptom severity given a history of bipolar disorder with the YMRS
timeFrame: baseline, 12 weeks
measure: Change in psychiatric symptom severity for a history of post traumatic stress disorder (PTSD)
timeFrame: baseline, 12 weeks
measure: Change in psychiatric symptom severity for a history of schizophrenia/schizophrenic disorders.
timeFrame: baseline, 12 weeks
measure: Change in subjective quality of life
timeFrame: baseline, 12 weeks
measure: Change in overall functioning
timeFrame: baseline, 12 weeks
Secondary outcomes:
measure: Sustainable change in substance use
timeFrame: 3 months, 6 months
measure: Sustainable change in psychiatric symptom severity for a history of Major Depressive Disorder (MDD)
timeFrame: 3 months, 6 months
measure: Sustainable change in psychiatric symptom severity given a history of bipolar disorder with the BDRS
timeFrame: 3 months, 6 months
measure: Sustainable change in psychiatric symptom severity given a history of bipolar disorder with the YMRS
timeFrame: 3 months, 6 months
measure: Sustainable change in psychiatric symptom severity for a history of post traumatic stress disorder (PTSD)
timeFrame: 3 months, 6 months
measure: Sustainable change in psychiatric symptom severity for a history of schizophrenia/schizophrenic disorders.
timeFrame: 3 months, 6 months
measure: Sustainable change in subjective quality of life
timeFrame: 3 months, 6 months
measure: Sustainable change in overall functioning
timeFrame: 3 months, 6 months
measure: Feasibility of the drama therapy intervention
timeFrame: 12 weeks
measure: Acceptability of the drama therapy intervention
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Boston
country: United States
facility: Boston Medical Center
state: Massachusetts
Study officials:
affiliation: Boston Medical Center, Psychiatry Department
name: William-Bernard Reid-Varley, MD MPH
role: PRINCIPAL_INVESTIGATOR
References: